Cargando…

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations

This study aimed to elucidate the association of the content of mutant epidermal growth factor receptor (EGFR) deoxyribonucleic acid (DNA) with the treatment response to EGFR-tyrosine kinase inhibitor (TKI) and survival in patients with lung cancer. This retrospective cohort study included 77 lung a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hung, Ming-Szu, Lung, Jr-Hau, Lin, Yu-Ching, Fang, Yu-Hung, Hsieh, Meng-Jer, Tsai, Ying-Huang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937916/ https://www.ncbi.nlm.nih.gov/pubmed/27368002 http://dx.doi.org/10.1097/MD.0000000000003991

Ejemplares similares

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report
por: Jiang, Yiqian, et al.
Publicado: (2021)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

(18)F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs
por: Huang, Yu-Erh, et al.
Publicado: (2022)

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis
por: Huang, Wu Feng, et al.
Publicado: (2015)

Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients
por: Hung, Ming-Szu, et al.
Publicado: (2019)

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Mao, Chen, et al.
Publicado: (2015)

High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs
por: Deng, Chao, et al.
Publicado: (2019)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review
por: Chen, Xiaoli, et al.
Publicado: (2023)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series
por: Li, Shih-Hong, et al.
Publicado: (2015)

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma
por: Ju, Qing, et al.
Publicado: (2021)

Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2018)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma
por: Min, Weili, et al.
Publicado: (2021)

Lung adenocarcinoma with EGFR gene mutation metastatic to the uterine cervix: A case report
por: Wang, Yong, et al.
Publicado: (2020)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study
por: Yu, Yuman, et al.
Publicado: (2021)

Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
por: Chen, Yanxin, et al.
Publicado: (2019)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma
por: Isaka, Tetsuya, et al.
Publicado: (2015)

Long-term survival in a patient with advanced non-smoking lung adenocarcinoma and no EGFR mutation after comprehensive therapy with EGFR-TKI-based therapy: A case report
por: Zhang, Qianyu, et al.
Publicado: (2022)

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs
por: Chiu, Tzu-Hsuan, et al.
Publicado: (2021)

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer
por: Ito, Takashi, et al.
Publicado: (2021)

Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma
por: Ma, Xiaoyan, et al.
Publicado: (2016)

Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study
por: Wang, Yuxiang, et al.
Publicado: (2022)

Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis
por: Hong, Xiaohua, et al.
Publicado: (2022)

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
por: Karachaliou, Niki, et al.
Publicado: (2019)

Bone metastatic carcinoma with EGFR amplification and mutation: A case report and literature review
por: Du, Hong-Juan, et al.
Publicado: (2023)

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR‐TKIs
por: Masuda, Ken, et al.
Publicado: (2018)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
por: Zhang, Guowei, et al.
Publicado: (2017)

Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report
por: Zhao, Nan, et al.
Publicado: (2022)

Breast metastasis from EGFR/ALK negative lung adenocarcinoma: A case report
por: Cao, Liyu, et al.
Publicado: (2020)

EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression
por: An, Na, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4ps7gniasotpjjuk0hdje5dm0i